Intravitreal injection therapy in the treatment of noninfectious uveitis

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 110-121

  Modorati, Giulio ^a   Miserocchi, Elisabetta ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ARTICLE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; UVEITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; UVEITIS;

EID: 84860880352     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336471     Document Type: Article

References (62)

1. de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, Lehoang P, Lightman S: Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-470.
2. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG: Drug delivery to the posterior segment of the eye. Drug Discov Today 2011;16:270-277.
3. Duvvuri S, Majumdar S, Mitra AK: Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56. (Pubitemid 36193650)
4. Kuppermann BD, Loewenstein A: Drug delivery to the posterior segment of the eye. Dev Ophthalmol 2010;47:59-72.
5. Lobo AM, Sobrin L, Papaliodis GN: Drug delivery options for the treatment of ocular inflammation. Semin Ophthalmol 2010;25:283-288.
6. Maurice D: Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001;17: 393-401. (Pubitemid 32888812)
7. Yasukawa T, Tabata Y, Kimura H, Ogura Y: Recent advances in intraocular drug delivery systems. Recent Pat Drug Deliv Formul 2011;5:1-10.
8. Sampat KM, Garg SJ: Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178-183.
9. Rodrigues EB, Grumann A Jr, Penha FM, Shiroma H, Rossi E, Meyer CH, Stefano V, Maia M, Magalhaes O Jr, Farah ME: Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J Ocul Pharmacol Ther 2011;27: 197-203.
10. Pe'er J, Hochberg FH, Foster CS: Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 2009;17:299-306.
11. Deng SX, Penland S, Gupta S, Fiscella R, Edward DP, Tessler HH, Goldstein DA: Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model. Invest Ophthalmol Vis Sci 2006;47:1516-1521. (Pubitemid 46780760)
12. Hardwig PW, Pulido JS, Erie JC, Baratz KH, Buettner H: Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142:883-885. (Pubitemid 44584144)
13. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL: Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116:797-801.
14. Bae Jh, Lee SC: Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behçet disease. Retina 2011, Epub ahead of print.
15. Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK: Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. J Ocul Pharmacol Ther 2011;27:151-156.
16. Li S, Tang S, Li W, Li D Yan Ke Xue Bao: Experiment study of retinal ultrastructure after intravitreal FK506. Yan Ke Xue Bao 2004;20:34-38.
17. Ishikawa T, Hokama H, Katagiri Y, Goto H, Usui M: Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Eye Res 2005;30: 93-101. (Pubitemid 40516085)
18. Oh-i K, Keino H, Goto H, Yamakawa N, Murase K, Usui Y, Kezuka T, Sakai J, Takeuchi M, Usui M: Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats. Br J Ophthalmol 2007;91:237-242. (Pubitemid 46202878)
19. Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF: Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010;51:3575-3582.
20. Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB: Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-796. (Pubitemid 33031303)
21. Patel RD, Momi RS, Hariprasad SM: Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol 2011;26: 372-379.
22. Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis JN: Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Ocul Pharmacol Ther 2011;27:197-203.
23. Acharya NR, Hong KC, Lee SM: Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148:303-309.
24. Acharya NR, Sittivarakul W, Qian Y, Hong KC, Lee SM: Bilateral effect of unilateral ranibizumab in patients with uveitis related macular edema. Retina 2011;31:1871-1876.
25. El-Mollayess GM, Noureddine BN, Bashshur ZF: Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 2011;26:69-76.
26. Julián K, Terrada C, Fardeau C, Cassoux N, François C, LeHoang P, Bodaghi B: Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol 2011;89:179-184.
27. Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz-Mercado H, Ruiz-Moreno JM, Serrano MA: Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Pan-American Collaborative Retina Study Group. Retina 2011;31: 353-363.
28. Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS: Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114: 1574-1579.
29. Lott MN, Schiffman JC, Davis JL: Bevacizumab in inflammatory eye disease. Am J Ophthalmol 2009; 148:711-717.
30. Lasave AF, Zeballos DG, El-Haig WM, Díaz-Llopis M, Salom D, Arevalo JF: Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 2009;17:423-430.
31. Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA: Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveiti cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 2010;26:199-206.
32. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M: Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2011, Epub ahead of print.
33. Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L: Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011;29(suppl 67):S54-S57.
34. Kotaniemi K, SäiläH, Kautiainen H: Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011;5:1425-1429.
35. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P: Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010;117:1612-1616.
36. Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M: Longterm remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 2011;29(suppl 67):S58-S63.
37. Hosseini H, Safaei A, Khalili MR, Nowroozizadeh B, Eghtedari M, Farvardin M, Nowroozizadeh S, Tolide-Ie HR: Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 2009;19:818-823.
38. Farvardin M, Afarid M, Mehryar M, Hosseini H: Intravitreal infliximab for the treatment of sightthreatening chronic noninfectious uveitis. Retina 2010;30:1530-1535.
39. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N: Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80.
40. Siddique SS, Shah R, Suelves AM, Foster CS: Road to remission: a comprehensive review of therapy in uveitis. Expert Opin Investig Drugs 2011;20: 1497-1515.
41. de Smet MD, Okada AA: Cystoid macular edema in uveitis. Dev Ophthalmol 2010;47:136-147.
42. Edelman JL, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
43. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;7:171-178.
44. Taylor SR, Isa H, Joshi L, Lightman S: New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010;224(suppl 1):46-53.
45. Peyman GA, Lad EM, Moshfeghi DM: Intravitreal injection of therapeutic agents. Retina 2009;29: 875-912.
46. Tao Y, Jonas JB: Intravitreal triamcinolone. Ophthalmologica 2011;225:1-20.
47. Kok H, Lau C, Maycock N, McCluskey P, Lightman S: Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916, e1-e 7.
48. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J: Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108: 765-772. (Pubitemid 32238474)
49. Martidis A, Duker JS, Puliafito CA: Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 2001;119:1380-1383. (Pubitemid 32994890)
50. Jonas JB, Kreissig I, Degenring RF: Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136: 384-386. (Pubitemid 36904101)
51. Sutter FK, Gillies MC: Intravitreal triamcinolone for radiation-induced macular edema. Arch Ophthalmol 2003;121:1491-1493. (Pubitemid 37243759)
52. Sirimaharaj M, Robinson MR, Zhu M, Csaky KG, Donovan B, Sutter F, Gillies MC: Intravitreal injection of triamcinolone acetonide for immune recovery uveitis. Retina 2006;26:578-580. (Pubitemid 44620407)
53. Scott IU, Flynn HW Jr, Rosenfeld PJ: Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol 2003;136:737-739. (Pubitemid 37153193)
54. Sampat KM, Garg SJ: Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21: 178-183.
55. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122:336-340. (Pubitemid 38314193)
56. Jonas JB, Kreissig I, Degenring R: Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27. (Pubitemid 36071773)
57. Jonas JB, Kreissig I, Degenring R: Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611. (Pubitemid 40949559)
58. Sallam A, Taylor SR, Lightman S: Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol 2011;22:517-522.
59. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, et al.: Influence of dosage from on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci 2009;50:4887-4897.
60. Baranano DE, Kim SJ, Edelhauser HF, Durairaj C, et al.: Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009;93: 1387-1390.
61. Kim SJ, Adams NA, Toma HS, Belair ML, et al.: Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008;28:595-605. (Pubitemid 351589569)
62. Soheilian M, Karimi S, Ramezani A, Peyman GA: Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010;30:509-515.